Characterization of the p33 Subunit of Eukaryotic Translation Initiation Factor-3 from Saccharomyces cerevisiae*

Parisa Hanachi, John W. B. HersheyDagger , and Hans-Peter Vornlocher§

From the Department of Biological Chemistry, University of California School of Medicine, Davis, California 95616

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Eukaryotic translation initiation factor-3 (eIF3) is a large multisubunit complex that binds to the 40 S ribosomal subunit and promotes the binding of methionyl-tRNAi and mRNA. The molecular mechanism by which eIF3 exerts these functions is incompletely understood. We report here the cloning and characterization of TIF35, the Saccharomyces cerevisiae gene encoding the p33 subunit of eIF3. p33 is an essential protein of 30,501 Da that is required in vivo for initiation of protein synthesis. Glucose repression of TIF35 expressed from a GAL1 promoter results in depletion of both the p33 and p39 subunits. Expression of histidine-tagged p33 in yeast in combination with Ni2+ affinity chromatography allows the isolation of a complex containing the p135, p110, p90, p39, and p33 subunits of eIF3. The p33 subunit binds both mRNA and rRNA fragments due to an RNA recognition motif near its C terminus. Deletion of the C-terminal 71 amino acid residues causes loss of RNA binding, but expression of the truncated form as the sole source of p33 nevertheless supports the slow growth of yeast. These results indicate that the p33 subunit of eIF3 plays an important role in the initiation phase of protein synthesis and that its RNA-binding domain is required for optimal activity.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

There are five major steps involved in initiation of eukaryotic protein synthesis: dissociation of ribosomes into 40 S and 60 S subunits, binding of Met-tRNAi to the 40 S ribosomal subunit; binding of mRNA to the 40 S preinitiation complex; scanning and initiation codon recognition, and the joining of the 60 S subunit to the 40 S initiation complex (1, 2). The initiation phase is promoted by at least 10 soluble proteins known as eukaryotic initiation factors (eIFs).1 eIF3 is the largest and most complex initiation factor, comprising 10 or more subunits in mammalian cells (3) and up to eight subunits in yeast (4, 5). Several functions have been assigned to eIF3 in the translation initiation pathway in mammalian cells (1). It promotes dissociation of 80 S ribosomes into 40 S and 60 S subunits and stabilizes Met-tRNAi binding to the 40 S ribosomal subunit. eIF3 also is required for mRNA binding to 40 S and 80 S ribosomes in part through its interaction with eIF4G (6) and/or eIF4B (7). Thus, eIF3 plays a central role in the initiation process.

To assist in elucidating the function of eIF3, attention has been given to the corresponding factor in yeast, where genetic approaches are feasible. The yeast eIF3 complex was purified on the basis of its stimulation of methionylpuromycin synthesis dependent on formation of 80 S initiation complexes in an assay composed of mammalian components (5). The active eIF3 preparation contains eight subunits with apparent molecular masses of 16, 21, 29, 33, 39, 62, 90, and 135 kDa (5). However, further studies revealed that the 29-kDa protein is a truncated form of p39 (8) and that the p21 protein originates by partial degradation of a 110-kDa protein.2 A somewhat similar preparation was isolated and purified by using its stimulation of protein synthesis in lysates prepared from a prt1-1 temperature-sensitive strain of yeast. The reported molecular masses of the subunits in this preparation of putative eIF3 are 130, 80, 75, 40, and 32 kDa (9).

The following yeast genes already have been characterized as encoding subunits of eIF3: SUI1 (p16) (10), TIF34 (p39) (8), GCD10 (p62) (11), PRT1 (p90) (5), and NIP1 (p93) (12). SUI1, encoding the smallest subunit of eIF3 (p16), was first identified genetically by recessive mutations that allow utilization of a UUG triplet as a translation initiation codon (13). TIF34 was cloned by obtaining a partial amino acid sequence of p39 and matching it to translated sequences in the data base (8) or by identifying the yeast homolog of the human TRIP1 protein (eIF3-p36) (14). The gene encoding p62 was identified through mutations that constitutively derepress the expression of GCN4 in rich medium (11). The p90 (Prt1) subunit was shown to affect Met-tRNAi binding to the 40 S ribosomal subunit (15, 16). The gene for p93 (NIP1) was first identified through a mutation that affects nuclear import of proteins (17). Analysis of strains carrying temperature-sensitive mutations in each of these five genes demonstrated that the proteins are required for initiation of protein synthesis in vivo (11-15).

Genes encoding the p135 (TIF31) and p110 (TIF32) subunits have been identified,2 and a preliminary account of their cloning has been published (4). To complete the cloning of the genes coding for yeast eIF3 subunits, we focused on the p33 subunit of eIF3 encoded by TIF35 (for translation initiation factor 3, the 5th subunit). TIF35 was first cloned through a two-hybrid analysis with p39 (TIF34) as bait (14). In this report, identification of the gene product as a component of eIF3 was based in large part on the work described here. During the preparation of this manuscript, reports were made identifying p33 in eIF3 complexes prepared by affinity chromatography or immunoprecipitation (18, 19). However, further characterization of p33 and its role in protein synthesis were not addressed in the reports. We describe here the cloning of TIF35, characterization of the function of p33 in protein synthesis, and analysis of its RNA recognition motif (RRM). This completes the detailed characterization of the genes encoding eight eIF3 subunits in yeast.

    MATERIALS AND METHODS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Strains and Media-- Escherichia coli strain XL1-Blue was used for plasmid propagation. The various Saccharomyces cerevisiae strains used in this work are based on strain W303-1A (MATa, leu2-3,112 his3-11,15 ade2-1 trp1-1 can1-100) or its isogenic diploid, W303 (20). Yeast cells were grown at 30 °C in YP or synthetic (S) medium supplemented with the relevant amino acids and 2% glucose (YPD or SD) or 2% galactose (YPG or SG) as described previously (21); growth was monitored by measuring absorbance at 600 nm (A600). Sporulation was carried out at room temperature on plates containing 0.3% potassium acetate, 0.02% raffinose, and 10 µg/ml each amino acid. Tetrad dissections and DNA transformations were carried out by standard procedures (22).

Cloning and Disruption of TIF35-- The yeast gene encoding eIF3-p33 was tentatively identified as a homolog of the gene for mammalian eIF3-p44. The mouse eIF3-p44 sequence (34) was used to conduct a TblastN search of the entire yeast genome sequence,3 and a putative protein was identified whose amino acid sequence exhibits 33.3% identity to mouse eIF3-p44. The coding sequence, together with flanking regions, was amplified from total yeast genomic DNA by PCR. The upstream (5'-CTCTTCACGATCTGCAAAAGTCCCAACATT-3') and downstream, (5'-GCTTATGGTGGTGGTGCTTCTTATAGCGCC-3') primers generate a single 2.1-kb DNA fragment. The fragment was gel-purified and subcloned into pNoTA (5 Prime right-arrow 3 Prime, Inc., Boulder, CO ) to create pNo-TIF35. Sequencing confirmed that the 2.1-kb insert contains an 825-base pair open reading frame (ORF) with 607 and 674 base pairs of DNA flanking the 5'- and 3'-ends, respectively.

To disrupt the TIF35 gene, pNo-TIF35 was digested with BsaAI and BsmI to remove 91% of the TIF35 coding region, and a 1.7-kb BamHI DNA fragment containing HIS3 was inserted to generate pNoTAtif35::HIS3. The upstream and downstream cloning primers described above were used to generate a 3.1-kb tif35::HIS3 PCR fragment, which was transformed into the diploid yeast strain W303 to create a one-step gene deletion/disruption (23). One of the stable His+ transformants (PH33D-7) was selected, and the disruption of one of the TIF35 genes was confirmed by Southern blot analysis (data not shown).

Plasmid Constructions-- pRS316-TIF35 was constructed by digesting pNo-TIF35 with BamHI and subcloning the resulting fragment into BamHI-cleaved pRS316 (American Type Culture Collection). p415Gal1-NH33 is a CEN4 LEU2 plasmid that allows expression of N-terminal His6-tagged p33 under the control of the GAL1 promoter. For its construction, the p33 coding sequence was PCR-amplified from pNo-TIF35 using 5'-CCCGGATCCGCCATGGGTAGAGGTTCTCACCATCACCATCACCATATGAGTGAACATATTCTGTGCATCTA-3' (tagged with BamHI and NcoI sites (underlined); the bases corresponding to the initiation codon of wild-type TIF35 are in boldface) and 5'-CCCGTCGACCTCGAGCATATTCTGTGCATCTA-3' (tagged with SalI and XhoI sites (underlined); the bases corresponding to the stop codon are in boldface). The resulting 0.9-kb DNA fragment was subcloned into pNoTA and sequenced, yielding pNo-NH33 (NH represents N terminus tagged with His6). To construct plasmids p415GalL-NH33 and p415GalS-NH33, pNo-NH33 was digested with BamHI and SalI, and the 0.9-kb fragment was subcloned into the BamHI/SalI sites of p415GalL and p415GalS, respectively (24). p415p33Delta C (kindly provided by M.-H. Verlhac, University of California, San Francisco) (14) is identical to p415Gal1-NH33, except that the encoded p33 lacks the C-terminal 71 amino acids.

To express a recombinant form of His-tagged p33 in E. coli, pET-NH33 was constructed by inserting the NcoI/XhoI fragment from pNo-NH33 into the corresponding sites in pET28c (Novagen). To generate pET-NH33Delta C, p415p33Delta C was digested with BamHI and SalI, and the 0.7-kb fragment was subcloned into pET28c digested with BamHI/SalI.

Construction of Haploid Yeast Strains PHS33, PHL33, and PH133-- Strain PH33D-7 was transformed with p415GalS-NH33, p415GalL-NH33, or p415p33Delta C, and transformants were selected on SD-His-Leu plates. The resulting transformants were sporulated, and their asci were dissected. Two, three, and four viable spores were obtained on YPG plates and were streaked on SG-His-Leu plates to identify TIF35-disrupted cells carrying p415GalS-NH33, p415GalL-NH33, and p415p33Delta C. The corresponding haploid strains were named PHS33, PHL33, and PH133, respectively.

Antibodies-- Rabbit antiserum against yeast eIF3 has been described previously (5). Rabbit anti-Prt1 antibody was a gift from A. G. Hinnebusch (National Institutes of Health), and affinity-purified rabbit anti-p39 antibody (14) was kindly provided by M.-H. Verlhac. To obtain anti-p33 antiserum, rabbit antibodies were raised against purified His6-p33 (BAbCo). For affinity-purified anti-recombinant p33 antibodies, His6-p33 was overexpressed from pET-NH33 in E. coli BL21(DE3), partially purified by Ni2+ affinity chromatography (Novagen), and fractionated by SDS-PAGE, followed by transfer to a polyvinylidene difluoride membrane (Millipore Corp.). The anti-p33 antiserum was incubated with a piece of the membrane containing His6-p33, and antibodies bound to His6-p33 were eluted with 0.2 ml of low-pH buffer (0.2 M glycine HCl and 1 mM EGTA, pH 2.5). The eluate was quickly neutralized with 0.2 ml of 100 mM Tris-HCl, pH 8.8; diluted with 1 volume of Blotto (0.5% (w/v) nonfat dry milk in 10 mM Tris-HCl, pH 7.4, 150 mM NaCl, and 0.075% (v/v) Tween 20); and stored frozen at -80° C. A second batch of affinity-purified anti-p33 antibodies was prepared similarly, but from the anti-eIF3 antiserum, and was used as indicated in the figure legends. Anti-p135 and anti-p110 antibodies were affinity-purified against recombinant His6-tagged p135 and p110 as described elsewhere.2

Analysis of Polysome Profiles-- Strains PHS33 and W303-1A were grown in YPG medium at 30° C to early log phase and shifted into YPD medium. Five, nine, and twelve hours after the shift to glucose, cycloheximide was added to a final concentration of 100 µg/ml, followed by quick cooling of the cultures on ice. The cells were harvested by centrifugation and washed with buffer A (10 mM Tris-HCl, pH 7.4, 100 mM KCl, 10 mM MgCl2, and 1 mM dithiothreitol) plus 100 µg/ml cycloheximide. Cells were broken by vortexing with glass beads in lysis buffer (20 mM HEPES, pH 7.5, 5 mM MgCl2, 150 mM KCl, 5% (v/v) glycerol, and 1× CompleteTM protease inhibitors (Boehringer Mannheim)), and cell lysates were clarified by centrifugation at 20,000 × g for 10 min at 4° C. Aliquots (10 A260 units) from each extract were fractionated on 15-45% sucrose gradients in buffer A by centrifugation at 38,000 rpm in a Beckman SW 40 rotor for 2.25 h at 4° C. The gradients were analyzed by upward displacement, and A254 profiles were obtained with a density gradient fractionator and UV monitor (Isco Model 185).

Measurement of Protein Synthesis Rates-- Strains W303-1A and PHS33 were grown overnight in SG complete minus methionine medium. Cells were harvested, washed in water, and resuspended in either SG complete minus methionine or SD complete minus methionine medium at a density of 0.05 A600. During incubation at 30° C, cells corresponding to 1 A600 unit were withdrawn at the indicated time points, harvested, washed in buffer A, and resuspended in 300 µl of the same medium containing 100 µCi of [35S]methionine (1 × 106 Ci/mol). The cells were incubated at 30° C for 5 min, followed by addition of 1 ml of a "stop buffer" containing 1.2 mg/ml nonradioactive methionine and 0.1 mg/ml cycloheximide in lysis buffer. Cells were disrupted with glass beads, and proteins from the cleared lysate were precipitated with 10% trichloroacetic acid. The pellet was washed with acetone and dissolved in 200 µl of 1% SDS. The incorporation of [35S]methionine into total protein was determined by counting radioactivity in an aliquot of the SDS extract. The protein concentration of the SDS extract was determined by the micro-BCA protein assay reagent kit (Pierce) as described by the manufacturer. The rate of protein synthesis is expressed as cpm × min-1 × µg of protein-1.

Immobilized Metal Affinity Chromatography-- Cells harvested at an A600 of 0.9-1 were disrupted with glass beads in lysis buffer by eight 30-s pulses in a Bead Beater (BioSpec Products, Inc.). The lysate was centrifuged for 15 min at 12,000 × g at 4° C, and the supernatant was centrifuged at 65,000 rpm in a Beckman TL100.4 rotor for 80 min at 4° C. The ribosomal pellet was suspended in 500 mM KCl in lysis buffer and centrifuged as described above. The resulting ribosomal salt wash enriched in eIF3 was incubated in batch for 1 h at 4° C with 0.8 ml of HIS-bindTM resin (Novagen) equilibrated with binding buffer (20 mM Tris-HCl, pH 7.9, 10% (v/v) glycerol, 30 mM imidazole, and 500 mM NaCl). After pouring the resin into a column, unbound proteins were removed by washing with 40 bed volumes of binding buffer, and eIF3 was eluted with the same buffer containing 500 mM imidazole. Eluted fractions were analyzed by SDS-PAGE and Western immunoblotting.

Northwestern Blot Analysis-- Plasmid pRIB-S1 (kindly provided by J. Warner, Albert Einstein University) carrying a copy of the yeast rDNA gene was used as template to amplify two fragments of yeast 18 S rDNA overlapping at the unique SacI site. rDNA nucleotides 1-1248 were amplified with primers 5'-CCCCTCGAGTATCTGGTTGATCCTGCCAG-3' (introducing an XhoI site (underlined) upstream of the first rDNA nucleotide) and 5'-CCCGAATTCGAGCTCTCAATCTGTCAATC-3' (introducing an EcoRI site downstream of the SacI site in the rDNA). Nucleotides 1243-1800 were amplified with primers 5'-CCCTCGAGGAGCTCTTTCTTGATTTTGTG-3' (introducing an XhoI site upstream of the SacI site) and 5'-CCCATCGATTAATGATCCTTCCGCAGGTT-3' (introducing a ClaI site after the last rRNA nucleotide). PCR products were cloned into pNoTA to generate pNo18S-5' and pNo18S-3', and the sequence was verified for both constructs. To construct templates for in vitro transcription under control of the T7 RNA polymerase promoter, the XhoI/EcoRI fragment from pNo18S-5' was cloned into pSP73 digested with XhoI/EcoRI to generate pSP18S-5'. pSP18S-3' was created by ligating the XhoI/ClaI fragment from pNo18S-3' into XhoI/ClaI-digested pSP73. Ligating a SacI/ClaI fragment from pNo18S-3' into the SacI/ClaI sites of pSP18S-5' resulted in pSP18S-fl. pSP18S-fl and pSP18S-3' were linearized with ClaI and transcribed with T7 RNA polymerase to yield rRNA-(1-1800) and rRNA-(1243-1800), respectively. pSP18S-5' digested with EcoRI and BstBI generated rRNA-(1-1248) and rRNA-(1-264), respectively. To synthesize rRNA-(263-1248), pSP18S-5' was digested with XhoI and BstBI, blunt-ended with Klenow DNA polymerase, religated, and digested with EcoRI prior to transcription. All T7 transcripts carry the sequence 5'-GGGAGACCGGCCUCGAG at the 5'-end of the rRNAs, corresponding to the pSP73 sequence following the transcription start site. In vitro transcription was carried out in the presence of 50 µCi of [alpha -32P]UTP (800 Ci/mmol) with the T7/SP6 transcription MAXIscript kit (Ambion Inc.) according to the manufacturer's recommendations. Unincorporated nucleotides were removed using MicroSpinTM S-200 HR columns (Amersham Pharmacia Biotech). The 32P-labeled beta -globin mRNA was prepared as described previously (25). Isotopically labeled transcripts were analyzed on denaturing 4% (for long transcripts) or 5% (for shorter transcripts) polyacrylamide gels.

For Northwestern RNA binding experiments, purified His6-p33 (3 µg), His6-p33Delta C (3 µg), and yeast lysate (10 µg) were subjected to SDS-PAGE and electrotransferred to polyvinylidene difluoride membranes. The membranes were treated for 20 min with binding buffer containing 20 mM HEPES-KOH, pH 7.5, 2 mM Mg(OAc)2, 75 mM KOAc, 1 mM EDTA, 1 mM dithiothreitol, 0.2% (w/v) CHAPS, 1 mg/ml E. coli tRNA, and 200 units of ribonuclease inhibitor (Amersham Pharmacia Biotech). Membranes were then incubated for 20 min with 200,000 cpm/ml of the 32P-labeled 18 S rRNA or beta -globin transcripts in 8 ml of binding buffer. The blots were washed three times for 5 min each with binding buffer and subjected to autoradiography.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Cloning and Characterization of TIF35-- When this work was initiated, the gene encoding the 33-kDa subunit of eIF3 had not been identified. An attempt to obtain partial amino acid sequences from tryptic digests of p33 from purified yeast eIF3 was not successful. However, at this time, partial amino acid sequence information was being developed in the laboratory (34) for one of the last subunits of mammalian eIF3 to be characterized, namely eIF3-p44. The mouse p44 amino acid sequence was used to search the yeast data base as described under "Materials and Methods," and an ORF encoding a putative homolog of mammalian eIF3-p44 was identified. Since the yeast ORF appeared to encode a 30.5-kDa protein, we considered it to be a good candidate for the gene for yeast eIF3-p33, which we named TIF35. Evidence reported below and elsewhere (18) shows that the protein product of TIF35 is a 33-kDa protein that is present in a complex with other known eIF3 subunits, confirming that the gene encodes the p33 subunit.

A 2.1-kb fragment of DNA containing TIF35 was amplified by PCR from yeast genomic DNA and cloned into the pNoTA vector to yield pNo-TIF35 as described under "Materials and Methods." The 2.1-kb DNA contains an ORF of 825 base pairs that codes for a protein of 274 amino acid residues with a calculated mass of 30,501 Da. The sequence context of the first AUG in the ORF, AUAAUG (the initiation codon is underlined), resembles the yeast consensus context, A(A/U)AAUG (26). This AUG is preceded by an in-frame UAG termination codon, whereas the next in-frame AUG is found far downstream at codon 117. Thus, the first AUG very likely serves as the initiation codon. Hybridization of 32P-labeled DNA probes (derived from the coding region) to a single band of genomic DNA individually digested with four different restriction enzymes suggested the presence of a single gene locus (data not shown).

Sequence comparisons revealed amino acid sequence identities/similarities of 35.8/46.9, 33.1/42.5, 33.3/43.1, and 33.6/47.3% when yeast eIF3-p33 was compared with the corresponding homologous proteins from Schizosaccharomyces pombe (GenBankTM/EBI accession number AB011823), human (U96074), mouse (AA109090, AA270800, and W18370), and Caenorhabditis elegans (Z50044; protein F22B5.2), respectively. When restricting the sequence comparison to the C-terminal 93-amino acid region of p33 that contains the RRM, identity/similarity values range between 43.7/56.3% for S. pombe and 36.4/47.7% for C. elegans. Therefore, eIF3-p33 appears to be present and moderately conserved in essentially all eukaryotic cells. In contrast, no homolog is found in Archaea sequences.

TIF35 Is an Essential Gene-- To examine whether or not TIF35 is an essential gene, we constructed a diploid strain, PH33D-7, in which one of the TIF35 genes is nearly entirely deleted and is replaced by HIS3, as described under "Materials and Methods." Tetrad analysis of PH33D-7 revealed that only two of the four spores in each of 30 asci formed colonies on rich medium (YPD), even after a long incubation at 30° C (data not shown). All viable spores were unable to grow on SD-His medium, suggesting that the phenotype of tif35::HIS3 is lethal. The segregation pattern of the tetrad spores (2+:2-) and the fact that no His+ segregants were found indicate that TIF35 is necessary for germination and/or cell viability.

To confirm that the lethal phenotype is due to disruption of TIF35, plasmid pRS316-TIF35, which expresses TIF35 from its own promoter on a centromeric plasmid carrying a URA3 marker gene, was constructed and transformed into PH33D-7. Ura+ transformants were selected; two were sporulated; and the resulting asci were dissected. Two, three, or four viable spore colonies per ascus were obtained (data not shown). Only one spore from the three viable tetrads or two from the four viable tetrads grew on SD-His plates, and all His+ spore colonies were also Ura+. Thus, spores containing the tif35::HIS3 allele must harbor the URA3 plasmid, which carries TIF35. The results show that TIF35 is the only gene affected and that the disruption is complemented by the cloned gene.

p33 Is Present in a Complex with Other eIF3 Subunits-- To obtain further evidence that TIF35 encodes a subunit of eIF3, we fused six histidine residues to the N terminus of p33 to create His6-p33. Strain PHL33, expressing His6-p33 as the sole source of this subunit, grows at the wild-type rate, indicating that the histidine tag is not deleterious to p33 function. Ribosomal salt wash fractions were prepared from strains expressing the wild-type (strain W303-1A) and histidine-tagged (strain PHL33) forms of p33, and the preparations were fractionated on Ni2+ affinity columns as described under "Materials and Methods." Bound proteins were eluted with 500 mM imidazole and analyzed by SDS-PAGE and Western immunoblotting (Fig. 1). When the blot was analyzed with antiserum to eIF3, no p33 or other eIF3 subunit was detected in the eluted fraction prepared from the strain expressing the wild-type form of p33 (W303-1A). However, with histidine-tagged p33 (strain PHL33), His6-p33 and numerous other eIF3 subunits were detected. Bands with mobilities corresponding to p135, p110, p90, p39, and p33 were readily identified. To confirm that these bands correspond to true eIF3 subunits, the blot was probed with antibodies affinity-purified against recombinant p135, p110, p39, and p33 and with an antiserum highly specific for Prt1p (p90). Each of these proteins was found bound to the Ni2+ affinity column only when p33 was histidine-tagged. We do not have antisera to the Nip1p (p93), Gcd10p (p62), and Sui1p (p16) subunits of eIF3, so we could not determine whether or not these proteins were present as well. However, it is apparent that p33 is present in complexes that contain most if not all of the putative eight subunits of eIF3.


View larger version (72K):
[in this window]
[in a new window]
 
Fig. 1.   Analysis of eIF3 subunits associated with histidine-tagged p33. Equal amounts of protein in the ribosomal salt wash (RSW) fractions prepared from strains W303-1A (expressing untagged p33) and PHL33 (expressing His6-p33) were fractionated by Ni2+ affinity chromatography as described under "Materials and Methods." Unbound (Wash) and bound (Eluate) fractions were analyzed by 7.5% SDS-PAGE (32), followed by immunoblotting onto polyvinylidene difluoride membranes with crude rabbit anti-eIF3 antiserum (upper panel) as well as affinity-purified antibodies (lower panels) as indicated on the right. The immunoblots were developed by nitro blue tetrazolium/5-bromo-4-chloro-3-indolyl phosphate (Sigma) color detection. wt, wild type.

Effect of TIF35 Depletion on Cell Growth and eIF3 Subunit Levels-- To investigate the function of eIF3-p33 in vivo, we depleted yeast cells of endogenous p33 and measured the effect of such depletion on cell growth and eIF3 subunit levels. As described under "Materials and Methods," we placed the TIF35 ORF under the glucose-repressible GALS promoter, an attenuated form of the GAL1 promoter (24). The strain carrying this construct as the sole source of TIF35, called PHS33, was grown in galactose-containing medium to early exponential growth phase and then transferred to glucose medium to turn off transcription of TIF35 from the GALS promoter. PHS33 in liquid cultures containing galactose as the carbon source grew with a doubling time of 90 min, comparable to that of the parental strain, W303-1A (Fig. 2B). When shifted to glucose-containing medium, strain W303-1A (in which p33 expression occurs from its own promoter) grew with a doubling time of ~90 min (Fig. 2A). In contrast, the growth rate of PHS33 began to decrease after about four generations (6 h), and the apparent growth rate was drastically reduced after 12 h (Fig. 2A). The very slow rate of growth seen thereafter may be due to extremely low levels of expression of TIF35 resulting from incomplete repression of transcription by glucose. The near-cessation of growth is consistent with an essential role for eIF3-p33.


View larger version (17K):
[in this window]
[in a new window]
 
Fig. 2.   Effect of p33 depletion on cell growth. Strains W303-1A (solid lines) and PHS33 (dashed lines) were initially grown in YPG medium and then diluted to an A600 of 0.03 in either YPD (A) or YPG (B) medium. Cultures were maintained in logarithmic growth phase throughout the experiment by diluting them to an A600 of 0.05 once they reached an absorbance of 0.5. The readings above an absorbance of 0.5 are calculations, taking into account the dilutions made. The results are representative of 5 independent experiments.

The levels of p33 and other eIF3 subunits in lysates prepared from W303-1A and PHS33 cells were determined at 5, 9, and 12 h after shift from galactose to glucose medium. Equal amounts of whole cell lysates were subjected to SDS-PAGE and Western immunoblotting with anti-eIF3 antibodies (Fig. 3, upper panel). The level of p33 in cell lysates prepared from the W303-1A strain remained constant up to 12 h (lane 8). In contrast, the level of p33 in strain PHS33 was greatly diminished after 9 h (lane 3), and the protein was nearly undetectable at 12 h (lane 4) after the shift to glucose. Interestingly, depletion of p33 was accompanied by a strongly reduced amount of p39, but not of the other eIF3 subunits examined here. This is seen clearly in the Western immunoblots made with antibodies affinity-purified against recombinant p135, p110, p39, and p33 and with a highly specific anti-Prt1p (p90) antiserum (Fig. 3, lower panels). The levels of p135, p110, and p90 did not change, whereas p39 and p33 were strongly reduced at 9 h (lane 3) and 12 h (lane 4). The experiments were performed at least five times, each time resulting in a depletion of only p33 and p39. The results suggest an important role of p33 in stabilizing the p39 subunit in the cell. The observation is consistent with our earlier results (14) and the results of Asano et al. (19) that demonstrate that p39 interacts with p33 in the yeast two-hybrid assay and that overexpression of p33 suppresses the slow growth phenotype of tif34-ts mutants. These observations support the view that p33 is physically associated with p39 in the eIF3 complex.


View larger version (82K):
[in this window]
[in a new window]
 
Fig. 3.   Immunoblot analysis of eIF3 subunits. Lysates were prepared from strains W303-1A and PHS33 harvested after shifting from galactose (G) to glucose (D) at the times indicated and as shown by arrows in Fig. 2 as described under "Materials and Methods." Lane 1, 0 h; lanes 2 and 7, 5 h; lane 3, 9 h; lanes 4 and 8, 12 h. Similarly, strain PHS33 was diluted into galactose medium. Lane 5, 5 h; lane 6, 12 h. The concentration of protein in each cell lysate was determined (33), and equal amounts (30 µg) were examined by 7.5% SDS-PAGE and immunoblotting as described in the legend to Fig. 1. Equal loading of lysate protein was confirmed by Coomassie Blue staining of identical gels run in parallel (data not shown). The antibodies used are indicated on the right, and the migration positions of the eIF3 subunits are labeled on the left. Only the relevant portions of the membrane are shown. rc, recombinant.

p33 Depletion Inhibits Protein Synthesis in Vivo-- The observation that TIF35 is an essential gene that encodes the p33 subunit of eIF3 suggests that p33 is required for initiation of translation. To test this idea, we first analyzed the effect of p33 depletion on protein synthesis in vivo. The rate of protein synthesis in strain PHS33 was measured by pulse-labeling cells for 5 min at various times following the shift from galactose- to glucose-containing medium (Fig. 4). During the first 3 h of growth in glucose, the rate of protein synthesis remained constant, probably due to the presence of pre-existing p33 in the cells. Subsequently, the rate of protein synthesis decreased to ~20% by 9 h, the time when the level of p33 was low as judged by immunoblot analysis (Fig. 3). In contrast, when W303-1A was grown under the same conditions or PHS33 cells were grown in galactose-containing medium, the rate of protein synthesis remained constant and decreased only slightly as cells reached late exponential phase. The results establish that p33 is required for optimal translation in yeast cells.


View larger version (18K):
[in this window]
[in a new window]
 
Fig. 4.   Inhibition of protein synthesis in p33-depleted cells. W303-1A cells grown in YPD medium (D; open circle ), PHS33 cells grown in YPG medium (G; triangle ), and PHS33 cells shifted from YPG to YPD medium () were subjected to a 5-min pulse labeling at the indicated times as described under "Materials and Methods." The rate of [35S]methionine incorporation into protein was calculated as cpm × min-1 × µg of protein-1.

To gain further insight into the role played by eIF3-p33 in protein synthesis, polysome profiles were examined from PHS33 and W303-1A cells shifted to glucose medium. Lysates prepared from p33-depleted and non-depleted cells were subjected to sucrose gradient centrifugation, and the gradients were scanned for absorbance as described under "Materials and Methods." PHS33 cells harvested 5 h after the shift to glucose showed large polysomes (Fig. 5A), consistent with little or no inhibition of protein synthesis rates at this time (Fig. 4). The gradient profiles from p33-depleted PHS33 cells analyzed at 9 and 12 h (Fig. 5, B and C) showed a marked reduction in the amount of large polysomes, with a proportionate increase in the amount of 80 S ribosomes when compared with parental W303-1A cells (Fig. 5D). The percentage of ribosomes remaining in polysomes in the p33-depleted cells was ~10-15% compared with 65% in non-depleted W303-1A cells, consistent with the ~6-fold inhibition of protein synthesis observed at those times (Fig. 4). The data demonstrate that ribosomes run off mRNAs following depletion of p33. Such behavior is indicative of a severe decrease in the rate of translation initiation.


View larger version (18K):
[in this window]
[in a new window]
 
Fig. 5.   Analysis of polysome profiles. Exponentially growing cultures of strains W303-1A and PHS33 in YPG medium were shifted to YPD medium at the indicated times, and lysates were processed for polysome analysis by sucrose gradient centrifugation as described under "Materials and Methods." A, PHS33 (5 h in YPD medium); B, PHS33 (9 h in YPD medium); C, PHS33 (12 h in YPD medium); D, W303-1A (12 h in YPD medium). The results are representative of five independent experiments. Shown are absorbance profiles with sedimentation from left to right. The positions of the 80 S ribosomes are indicated by arrows.

eIF3-p33 Is An RNA-binding Subunit-- One function of the eIF3 complex is to promote the binding of mRNA to the 40 S ribosomal subunit (27, 28). Of the eight subunits of yeast eIF3, three contain RNA-binding motifs in their sequences: p90, p62, and p33. p62 (Gcd10p) binds RNA strongly when assayed by Northwestern blotting with a globin mRNA fragment (5). Both p90 (Prt1p) and p33 contain the RNP-1 and RNP-2 motifs found in a family of proteins possessing the RRM (29); however, RNA binding to these subunits was not detected by Northwestern blotting (10, 21). To assess the RNA-binding ability of p33, purified His6-p33 was subjected to Northwestern analysis with radiolabeled 18 S rRNA (Fig. 6B, lane 2) or beta -globin mRNA (Fig. 6C, lane 5). The protein bound either type of RNA, suggesting a lack of specificity (but see "Discussion" below). The possibility that p33 binds a specific region of the 18 S rRNA was examined by Northwestern blotting with 32P-labeled fragments of 18 S rRNA (Fig. 6, A and C). All fragments bound, again suggesting little or no specificity. The role of the RRM in RNA binding was examined by testing purified recombinant His6-p33Delta C. No binding to 18 S rRNA was detected (Fig. 6B, lane 3). The results demonstrate that p33 has nonspecific RNA-binding activity and that its C-terminal RRM is essential for the RNA-binding function.


View larger version (30K):
[in this window]
[in a new window]
 
Fig. 6.   Northwestern blot analysis of p33 binding to RNA. A, scheme of the in vitro transcripts of 18 S rRNA used. Radiolabeled transcripts were prepared with T7 RNA polymerase as described under "Materials and Methods." The numbers on the right describe the range of nucleotides in the transcript. B, upper panel: Northwestern blotting of His6-p33 and His6-p33Delta C. His6-p33 and His6-p33Delta C were produced in E. coli BL21(DE3) and purified as described under "Materials and Methods." Purified recombinant (rc) proteins (2-3 µg) and 20 µg of yeast lysate were subjected to 7.5% SDS-PAGE, followed by blotting onto a polyvinylidene difluoride membrane and probing with 32P-labeled 18 S rRNA-(1-1800) as described under "Materials and Methods." Lower panel: Coomassie Blue staining of recombinant His6-p33 and His6-p33Delta C in the blot above. The migration positions of full-length and truncated recombinant tagged p33 proteins are shown; only a portion of the blot is shown. C, Northwestern blotting of His6-p33 (2-3 µg) with truncated forms of 18 S rRNA and beta -globin mRNA. Only the portions of the blots containing tagged p33 are shown.

The C-terminal RNA-binding Domain of p33 Is Not Essential for Cell Growth-- To assess whether or not the RRM of p33 is essential, the C-terminal 71 amino acid residues were deleted, thereby removing the RNP-1 element and most of the RRM (14). p415p33Delta C, which expresses the C-terminal truncated p33 (p33Delta C) from a GAL1 promoter, was transformed into strain PH33D-7, and transformants were sporulated and analyzed by tetrad dissection. From each ascus, two fast growing haploid cells plus none, one, or two very slow growing cells were obtained in galactose-containing medium (Fig. 7A). The slow growing haploid cells were His+, indicative of carrying the disrupted tif35::HIS3 gene on a chromosome, and Leu+, due to the presence of p415p33Delta C (Fig. 7B). One of the haploid slow growing colonies was selected and called PH133. Strain PH133 did not grow on glucose-containing medium, consistent with the plasmid being the only source of TIF35 expression. It exhibited a doubling time of 6 h in galactose-containing medium, thereby suggesting that the RRM is not absolutely essential when p33Delta C is expressed from a GAL1 promoter. The slow growth phenotype could be caused either by a reduced specific activity or by a reduced level of p33Delta C. To distinguish between these possibilities, the cellular levels of p33Delta C and p33 were measured by Western immunoblotting of lysates derived from strain PH133 and the parental strain, W303-1A (Fig. 7C). The band corresponding to full-length p33 was absent in PH133, and instead a strong band with the expected apparent molecular mass of 25 kDa was seen that was absent in W303-1A. The intensity of the p33Delta C band in PH133 is comparable to that of p33 in W303-1A, indicating that p33Delta C is stable and accumulates to wild-type levels. We conclude that the slow growth phenotype is caused by an appreciable loss of p33 activity due to the removal of its RRM.


View larger version (40K):
[in this window]
[in a new window]
 
Fig. 7.   Effect of deleting the C-terminal RNA-binding domain of p33 on cell growth. A, dissection of seven tetrads from PH33D-7 transformed with p415p33Delta C was carried out as described under "Materials and Methods." Spores are arranged vertically on a YPG plate as indicated by letters on the left and were allowed to germinate and grow at 30 °C for 5 days. A photograph of the plate is shown. B, the dissected tetrad shown in A (lane 3), which gives four viable spore colonies, was selected, and the four colonies were streaked onto SG-His-Leu and SD-His-Leu plates as indicated. The plates were incubated at 30 °C for 5 days and then photographed. C, equal amounts of protein (10 µg) from strain W303-1A (lane 1) and PH133 (lane 2) were subjected to SDS-PAGE and immunoblotting with anti-p33 antiserum as described in the legend to Fig. 1. Equal loading of the lysates was confirmed by Amido Black staining of a parallel gel and by the equal intensities of cross-reacting protein. A scan of a portion of the blot is shown; the bands corresponding to p33 and p33Delta C are identified.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Yeast eIF3 was purified in this laboratory based on its activity in an eIF3-dependent mammalian assay for the synthesis of methionylpuromycin (5). To elucidate the role of eIF3 in the initiation process, we have sought to determine the primary structures of all the eIF3 subunits by cloning the genes that encode them. Descriptions of the genes for p93, p90, p62, p39, and p16 have been published, whereas those for p135 and p110 have been completed.2 The studies described here on the p33 gene, TIF35, extend earlier work that identified p33 as part of eIF3 (14, 18, 19). Thus, the genes for all eight of the subunit proteins have been identified and characterized in detail.

The cloning of TIF35 was based initially on its homology (33% sequence identity and 43% similarity) to mouse or human eIF3-p44. Further evidence that the putative cloned gene actually encodes the p33 subunit of eIF3 follows. 1) TIF35 encodes a protein with a calculated mass of 30.5 kDa, close to the apparent mass of the 33-kDa subunit of eIF3. It should be noted, however, that the apparent mass of this protein depends on the gel system used, and values range from 32 to 36 kDa. 2) Antibodies raised against the product of TIF35 expressed in E. coli react with the p33 subunit in purified eIF3 preparations. 3) By using the yeast two-hybrid system and co-immunoprecipitations, p33 was shown to interact with a previously characterized subunit of eIF3, namely p39 (14, 19). 4) When p33 tagged with His6 is expressed in yeast as the sole source of p33, a complex is isolated by Ni2+ affinity chromatography that contains numerous other subunits of eIF3, namely p135, p110, p90, and p39. 5) The TIF35 gene product was identified by mass spectroscopy in a complex with p110, p93, His6-p90, and p39, which was isolated by Ni2+ affinity chromatography (18). 6) Depletion of p33 results in lowered levels of p39. 7) Finally, overexpression of p33 from TIF35 suppresses the temperature-sensitive phenotype of mutant forms of p39 (14, 19). These findings provide convincing evidence that p33 expressed from TIF35 is a subunit of yeast eIF3.

Deletion/disruption of TIF35 is lethal and, together with depletion experiments, shows that p33 is required for cell growth. Depletion also causes an inhibition of the initiation phase of protein synthesis as deduced from polysome profiles. This is consistent with p33 being a subunit of eIF3, and comparable effects on protein synthesis are seen when other eIF3 subunits are depleted or inactivated. However, a precise role for p33 in initiation cannot be determined from these experiments. Because p39 is depleted along with p33, the loss of eIF3 function could be due to the lack of p39, rather than p33 itself. The availability of cloned TIF35 should expedite the isolation of mutant forms of p33 that may shed light on its function.

One of the possible functions of p33 is to bind RNA. Possible targets are the 18 S rRNA in the 40 S ribosomal subunit, mRNA, and Met-tRNAi residing in the ternary complex with eIF2 and GTP. Northwestern blotting was used to examine binding to radiolabeled 18 S rRNA and beta -globin mRNA. Because p33 binds to all fragments of 18 S rRNA and to mRNA, it appears that the RNA-binding activity is nonspecific for both sequence and structure. The human homolog, eIF3-p44, also binds RNA nonspecifically (34). An important caveat is that there could be significant differences in RNA-binding affinities between the different RNA probes that are not detected by the method employed. Deletion of most of the C-terminal RRM results in loss of RNA binding as determined by Northwestern blotting. It is surprising, however, that the C-truncated protein, p33Delta C, nevertheless supports growth (albeit slow) of yeast as the sole source of the p33 subunit. Therefore, the RRM does not perform an essential function, but clearly is required for optimal activity of the protein.

For further insight into the RNA-binding properties of yeast eIF3-p33, a comparison was made of the RRM sequences of four other p33 homologs derived from S. pombe, C. elegans, Homo sapiens, and Mus musculus (Fig. 8). The RRM regions of p33 from these species share sequence identities/similarities with the RRM of S. cerevisiae p33 of 41/63, 32/53, 39/55, and 40/56%, respectively. In particular, each of the four putative beta -sheet structures appears well conserved, suggesting common functions. The RRMs of the five p33 homologs also are similar to the RRM in the spliceosomal protein U1A (Fig. 8). Structural data for a U1A-RNA interaction are available from crystallographic (30) and NMR (31) studies. The U1A RRM contains a four-stranded beta -sheet that is stabilized by two alpha -helices. The single-stranded loop of the RNA binds to the surface formed by the beta -sheets, interacting mainly with beta -sheets 1 and 3. Most amino acids required to form the hydrophobic core of the U1A RRM (Leu-17, Leu-26, Phe-34, Phe-59, and Ala-68) are also conserved in p33 and its homologs (residues denoted by solid squares in the figure). Half of the residues implicated in U1A binding to RNA also are conserved in p33 (solid circles), whereas half are not (open circles), especially those in beta -sheet 4. A striking difference corresponds to Tyr-13 in beta -sheet 1 of U1A, which is a basic amino acid residue in all of the p33 homologs. In U1A, Tyr-13 stacks with a C base in the RNA, whereas in p33, this interaction presumably is replace by ionic attraction between the basic amino acid and a phosphate in the RNA. The stacking interaction seen with U1A Gln-54 could be accomplished with the Leu or Phe residues in the p33 homologs. Although beta -sheets 2 and 4 differ in sequence from the corresponding regions in U1A, beta -sheet 2 in particular contains numerous basic residues that may contribute to RNA binding. The sequence similarities and differences between U1A and the p33 homologs suggest that slightly different modes of RNA binding may be involved that may contribute to different binding specificities.


View larger version (56K):
[in this window]
[in a new window]
 
Fig. 8.   Sequence comparisons of the RRM-containing C terminus of p33 from five species. The C-terminal sequences of S. cerevisiae (S.ce.) p33 and its homologs from S. pombe (S.po.), C. elegans (C.el.), human (H. sapiens (H.sa.)), and mouse (M. musculus (M.mu.)) are compared with the RRM sequence in the human U1A protein. Locations of the RNP motifs and secondary structure elements of U1A are indicated above the sequences. Numbering is according to the U1A protein. Residues important for forming the hydrophobic core of the RRM are denoted by solid squares. Solid and open circles indicate residues involved in U1A-RNA interactions that are conserved or not conserved, respectively, between U1A and p33 or its homologs.

Work from several laboratories has identified eight possible subunits in yeast eIF3: p135, p110, p93, p90, p62, p39, p33, and p16. Evidence for the presence of p135 and p110 in eIF3 will be published elsewhere.2 The p93 subunit, encoded by NIP1, has been seen in a complex with p110, p90, p39, and p33 obtained by Ni2+ affinity chromatography with His6-tagged p90 (18). As reported elsewhere, p90, p62, p39, and p16 are present in the various immunoprecipitates of eIF3 formed by antibodies to these proteins (5, 8, 10, 11). The sum of the evidence therefore indicates that a complex of eight subunits exists in yeast.

We show here that His6-tagged p33 allows the isolation of a complex in which p135, p110, p90, and p39 are positively identified with affinity-purified antibodies. Lacking antibodies to p93, we have not detected p93 in these preparations. Furthermore, the p93 subunit is readily degraded in extracts derived from strain W303 (12). Our results differ somewhat from those obtained by Phan et al. (18) with His6-tagged p90, where five eIF3 subunits were detected, namely p110, p93, p90, p39, and p33, but not p135. This complex of five subunits is active in stimulating Met-tRNAi binding to 40 S subunits in vitro and therefore may constitute the active "core" of eIF3. It is interesting that of the eight eIF3 subunits, only the five core subunits are homologous to mammalian eIF3 subunits. We believe that p135 associates with the eIF3 core complex, although its affinity is not so strong as that of the core subunits. The issue of the presence of p135 in eIF3 is addressed in detail elsewhere.2

Depletion of p33 causes loss of p39, but not of the p90, p110, and p135 subunits. On the other hand, depletion of p110 causes p90 to be degraded, whereas p39 and p33 are stable.2 These experiments suggest that eIF3 may have two major domains, one with p39 and p33 and the other with the larger subunits. The two domains might be connected by an interaction between p39 and p90, as shown by two-hybrid analyses (14, 19). Work is in progress to further elucidate the structure of eIF3 by employing a number of methods that detect protein-protein interactions. The characterization of TIF35 contributes to these studies. We anticipate that further detailed structural studies of eIF3 will help to elucidate the function of this key initiation factor.

    ACKNOWLEDGEMENTS

We thank J. Warner, A. G. Hinnebusch, and M.-H. Verlhac for providing clones and antibodies. We also thank A. G. Hinnebusch for communicating results prior to publication and S. Ribeiro and L. Phan for helpful discussions.

    FOOTNOTES

* This work was supported by National Institutes of Health Grant GM22135 and by a research fellowship from the Deutsche Forschungsgemeinschaft (to H.-P. V.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

The nucleotide sequence(s) reported in this paper has been submitted to the GenBankTM/EMBL Data Bank with accession number(s) AF004913.

Dagger To whom correspondence should be addressed. Tel.: 530-752-3235; Fax: 530-752-3516; E-mail: jwhershey{at}ucdavis.edu.

§ Present address: Institut für Molekularbiologie und Tumorforschung, Philipps Universitaet Marburg, 35033 Marburg, Germany.

2 H.-P. Vornlocher, P. Hanachi, S. Ribeiro, and J. W. B. Hershey, manuscript in preparation.

3 http://genome-www.stanford.edu/Saccharomyces/.

    ABBREVIATIONS

The abbreviations used are: eIFs, eukaryotic initiation factors; RRM, RNA recognition motif; PCR, polymerase chain reaction; kb, kilobase pair; ORF, open reading frame; PAGE, polyacrylamide gel electrophoresis; CHAPS, 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonic acid; RNP, ribonucleoprotein.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
  1. Merrick, W. C., and Hershey, J. W. B. (1996) in Translational Control (Hershey, J. W. B., Mathews, M. B., and Sonenberg, N., eds), pp. 31-69, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
  2. Pain, V. M. (1996) Eur. J. Biochem. 236, 747-771[Abstract]
  3. Brown-Luedi, M. L., Meyer, L. J., Milburn, S. C., Mo-Ping Yau, P., Corbett, S., and Hershey, J. W. B. (1982) Biochemistry 21, 4202-4206[Medline] [Order article via Infotrieve]
  4. Hershey, J. W. B., Asano, K., Naranda, T., Vornlocher, H.-P., Hanachi, P., and Merrick, W. C. (1996) Biochimie (Paris) 78, 903-907[CrossRef][Medline] [Order article via Infotrieve]
  5. Naranda, T., MacMillan, S. E., and Hershey, J. W. B. (1994) J. Biol. Chem. 269, 32286-32292[Abstract/Free Full Text]
  6. Lamphear, B. J., Kirchweger, R., Skern, T., and Rhoads, R. E. (1995) J. Biol. Chem. 270, 21975-21983[Abstract/Free Full Text]
  7. Méthot, N., Song, M. S., and Sonenberg, N. (1996) Mol. Cell. Biol. 16, 5328-5334[Abstract]
  8. Naranda, T., Kainuma, M., MacMillan, S. E., and Hershey, J. W. B. (1997) Mol. Cell. Biol. 17, 145-153[Abstract]
  9. Danaie, P., Wittmer, B., Altmann, M., and Trachsel, H. (1995) J. Biol. Chem. 270, 4288-4292[Abstract/Free Full Text]
  10. Naranda, T., MacMillan, S. E., Donahue, T. F., and Hershey, J. W. B. (1996) Mol. Cell. Biol. 16, 2307-2313[Abstract]
  11. Garcia-Barrio, M. T., Naranda, T., Vazquez de Aldana, C. R., Cuesta, R., Hinnebusch, A. G., Hershey, J. W. B., and Tamame, M. (1995) Genes Dev. 9, 1781-1796[Abstract]
  12. Greenberg, J. R., Phan, L., Gu, Z., deSilva, A., Apolito, C., Sherman, F., Hinnebusch, A. G., and Goldfarb, D. S. (1998) J. Biol. Chem. 273, 23485-23494[Abstract/Free Full Text]
  13. Yoon, H. J., and Donahue, T. F. (1992) Mol. Cell. Biol. 12, 248-260[Abstract]
  14. Verlhac, M.-H., Chen, R. H., Hanachi, P., Hershey, J. W. B., and Derynck, R. (1997) EMBO J. 16, 6812-6822[Abstract/Free Full Text]
  15. Feinberg, B., McLaughlin, C. S., and Moldave, K. (1982) J. Biol. Chem. 257, 10846-10851[Abstract]
  16. Evans, D. R. H., Rasmussen, C., Hanic-Joyce, P. J., Johnston, G. C., Singer, R. A., and Barnes, C. A. (1995) Mol. Cell. Biol. 15, 4525-4535[Abstract]
  17. Gu, Z., Moerschell, R. P., Sherman, F., and Goldfarb, D. S. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 10355-10359[Abstract]
  18. Phan, L., Zhang, X., Asano, K., Anderson, J., Vornlocher, H.-P., Greenberg, J. R., Goldfarb, D. S., Qin, J., and Hinnebusch, A. G. (1998) Mol. Cell. Biol. 18, 4935-4946[Abstract/Free Full Text]
  19. Asano, K., Phan, L., Anderson, J., and Hinnebusch, A. G. (1998) J. Biol. Chem. 273, 18573-18585[Abstract/Free Full Text]
  20. Thomas, B. J., and Rothstein, R. (1989) Cell 56, 619-630[Medline] [Order article via Infotrieve]
  21. Guthrie, C., and Fink, G. R. (1991) Guide to Yeast Genetics and Molecular Biology, Academic Press, Inc., San Diego, CA
  22. Struhl, K., Stinchcomb, D. T., Scherer, S., and Davis, R. W. (1979) Proc. Natl. Acad. Sci. U. S. A. 76, 1035-1039[Abstract]
  23. Rothstein, R. J. (1983) Methods Enzymol. 101, 202-211[Medline] [Order article via Infotrieve]
  24. Mumberg, D., Maller, R., and Funk, M. (1994) Nucleic Acids Res. 22, 5767-5768[Medline] [Order article via Infotrieve]
  25. Wei, C.-L., MacMillan, S. E., and Hershey, J. W. B. (1995) J. Biol. Chem. 270, 5764-5771[Abstract/Free Full Text]
  26. Cigan, A. M., and Donahue, T. F. (1987) Gene (Amst.) 59, 1-18[CrossRef][Medline] [Order article via Infotrieve]
  27. Benne, R., and Hershey, J. W. B. (1976) Proc. Natl. Acad. Sci. U. S. A. 73, 3005-3009[Abstract]
  28. Staehelin, T., Erni, B., and Schreier, M. H. (1979) Methods Enzymol. 60, 136-165[Medline] [Order article via Infotrieve]
  29. Burd, C. G., and Dreyfuss, G. (1994) Science 265, 615-621[Medline] [Order article via Infotrieve]
  30. Oubridge, C., Ito, N., Evans, P. R., Teo, C. H., and Nagai, K. (1994) Nature 372, 432-438[CrossRef][Medline] [Order article via Infotrieve]
  31. Avis, J. M., Allain, F. H., Howe, P. W., Varani, G., Nagai, K., and Neuhaus, D. (1996) J. Mol. Biol. 257, 398-411[CrossRef][Medline] [Order article via Infotrieve]
  32. Schägger, H., and von Jagow, G. (1987) Anal. Biochem. 166, 368-379[Medline] [Order article via Infotrieve]
  33. Bradford, M. M. (1976) Anal. Biochem. 72, 248-254[CrossRef][Medline] [Order article via Infotrieve]
  34. Block, K. L., Vornlocher, H.-P, and Hershey, J. W. B. (1998) J. Biol. Chem. 273, 31901-31908[Abstract/Free Full Text]


Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.